Concern around the lack of monitoring of proteinaceous subvisible particulates in the 0.1-10 mm range has been heightened (Carpenter et al., 2009, J Pharm Sci 98: 1202-1205), primarily due to uncertainty around the potential immunogenicity risk from these particles. This article, representing the op
An industrial organization perspective on the influenza vaccine shortage
β Scribed by F.M. Scherer
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 176 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0143-6570
- DOI
- 10.1002/mde.1349
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
This paper analyzes reasons advanced for the recent shortage of influenza vaccine in the United States and numerous other similar shortages in recent years. Explanations have included high regulatory costs, inadequate profitability, and mergers. Using Census data, it shows that vaccine producers realize unusually high priceβcost margins, but are probably also unusually capitalβintensive. Applying theories of scale economies to existing information, it identifies the extent to which, for diverse types of vaccines, economies of scale limit the number of vaccine producers, exposing the nation to stochastic shortage risk. A benefit/cost analysis explores whether it is economically worthwhile to maintain additional production sources with surge capacity. It is found that under plausible demand, external benefit, and stochastic supply failure conditions, such multiple sourcing yields more benefits than its cost. Copyright Β© 2007 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES